Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50

Rhea-AI Filing Summary

Aligos Therapeutics director Heather Preston received a new stock option grant. The award covers 5,860 shares of common stock with an exercise price of $5.50 per share and expires on June 25, 2036.

The option will vest and become exercisable in full on the earlier of the first anniversary of the June 25, 2026 grant date or immediately prior to the company’s 2027 annual stockholder meeting, provided she continues serving the company through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Preston Heather

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,860	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,860 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 5,860 options Exercise price: $5.50 per share Expiration date: June 25, 2036 +2 more

5 metrics

Option grant size 5,860 options Stock Option (Right to Buy) granted June 25, 2026

Exercise price $5.50 per share Strike price of granted stock options

Expiration date June 25, 2036 Option term for 5,860-share grant

Underlying shares 5,860 shares Common stock underlying the option

Post-transaction derivative holdings 5,860 options Total derivative securities held after grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, continuous service, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 5.5000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-25T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

continuous service financial

"subject to continuous service to the Issuer through such vesting date"

annual meeting financial

"immediately prior to the annual meeting in 2027 of the Issuer's stockholders"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:39 PM Accepted by SEC EDGAR 06/29/2026 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Preston Heather

(Last) (First) (Middle)

C/O ALIGOS THERAPEUTICS, INC.

1 CORPORATE DRIVE, 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.5	06/25/2026		A		5,860		(1)	06/25/2036	Common Stock	5,860	$0	5,860	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

	/s/ Lesley Ann Calhoun, as attorney-in fact for Heather Preston	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Heather Preston report in the latest Aligos Therapeutics (ALGS) Form 4?

Heather Preston reported receiving a stock option grant for 5,860 shares of Aligos Therapeutics common stock. The option is compensation-related, carries a $5.50 exercise price per share, and expires on June 25, 2036, according to the Form 4 disclosure.

Is the Heather Preston Form 4 for Aligos Therapeutics (ALGS) a purchase or a grant?

The Form 4 reflects a grant, not an open-market purchase. Preston received 5,860 stock options as a compensation award with a $5.50 exercise price, classified under transaction code A for grant, award, or other acquisition in the SEC filing.

When do Heather Preston’s Aligos Therapeutics (ALGS) options vest?

The options vest 100% on the earlier of the first anniversary of the June 25, 2026 grant date or immediately before Aligos Therapeutics’ 2027 annual stockholder meeting. Vesting is contingent on her continuous service to the company through the applicable vesting date.

What is the exercise price and expiration for Heather Preston’s ALGS stock options?

The granted stock options have a $5.50 exercise price per share and expire on June 25, 2036. This gives Heather Preston the right to buy 5,860 Aligos Therapeutics common shares at that fixed price until the expiration date.

How many Aligos Therapeutics (ALGS) derivative securities does Heather Preston hold after this Form 4?

After the reported transaction, Heather Preston holds 5,860 stock options as shown in the Form 4. These options each relate to one share of Aligos Therapeutics common stock and represent her recorded derivative position following the grant.